+5 more ↓
63%
Finnrick rating
#232 of 283 ranked vendors
211 of 326 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Qing Li Peptide's purity-focus record is strongest in GHK-Cu, Tirzepatide, and Retatrutide, where recent clean identity/purity/fill results offset earlier purity misses and fill swings. Evidence is deep and current but dispersed: TB-500, Tesamorelin, and BPC-157 carry repeated purity, identity, or large fill failures, with spotty batch detail.

methodology →
vendor intelligence report
Vendor Intelligence Report: Qing Li Peptide

Domain records, Wayback captures and supplier profiles point away from the Hong Kong-facing history Qing Li presents. The report maps cloned storefronts, exposed staff records and a Pioneer Peptide fee pattern seen in buyer reports.

33 pages6 risk factors assessed3 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.05
89%
35
2
Tirzepatide
$0.47
80%
44
3
Retatrutide
$1.00
79%
119
4
Ipamorelin
$0.60
70%
16
5
Melanotan II
$0.40
67%
7
6
PT-141
-
65%
6
7
Sermorelin
$1.00
56%
5
8
Cagrilintide
$1.80
55%
4
9
Survodutide
$3.00
47%
3
10
CJC-1295
$1.40
38%
18
11
BPC-157
$0.70
36%
31
12
Tesamorelin
$1.80
34%
21
13
TB-500
$1.20
22%
18
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%18 Mar 2026: 61%18 Mar 2026: 61%18 Mar 2026: 61%18 Mar 2026: 62%18 Mar 2026: 62%18 Mar 2026: 62%18 Mar 2026: 62%18 Mar 2026: 62%19 Mar 2026: 62%19 Mar 2026: 62%21 Apr 2026: 62%27 Apr 2026: 62%28 Apr 2026: 62%28 Apr 2026: 62%30 Apr 2026: 62%5 May 2026: 62%5 May 2026: 62%6 May 2026: 62%6 May 2026: 62%6 May 2026: 62%13 May 2026: 63%13 May 2026: 62%27 May 2026: 62%27 May 2026: 62%27 May 2026: 62%27 May 2026: 62%2 Jun 2026: 62%5 Jun 2026: 62%5 Jun 2026: 62%8 Jun 2026: 62%8 Jun 2026: 63%8 Jun 2026: 62%17 Jun 2026: 63%17 Jun 2026: 63%17 Jun 2026: 63%17 Jun 2026: 63%23 Jun 2026: 63%24 Jun 2026: 63%24 Jun 2026: 63%1 Jul 2026: 63%29 Jul 2026: current 63%61%62%63%Mar 26Jul 26
Qing Li Peptide test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
1 Jul 2026Pass
Retatrutide
lab nameView COA
24 Jun 2026Fail
BPC-157
lab nameView COA
24 Jun 2026Pass
Retatrutide
lab nameView COA
23 Jun 2026Pass
GHK-Cu
lab nameView COA
17 Jun 2026Pass
Tesamorelin
lab nameView COA
17 Jun 2026Pass
Retatrutide
lab nameView COA
17 Jun 2026Pass
Retatrutide
lab nameView COA
17 Jun 2026Pass
Tirzepatide
lab nameView COA
8 Jun 2026Pass
GHK-Cu
lab nameView COA
8 Jun 2026Pass
Tirzepatide
lab nameView COA
1-10 of 200

About Qing Li Peptide test results from Finnrick

Qing Li Peptide is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 13 peptides and 327 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Qing Li Peptide peptides in this dataset are Melanotan II (7 tests) and Semaglutide (0 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 200 recent tests.

Corrections
No corrections.